CD44v6 may influence ovarian cancer cell invasion and migration by regulating the NF‑κB pathway

Wang,Yanqing; Yang,Xiao; Xian,Shu; Zhang,Li; Cheng,Yanxiang

doi:10.3892/ol.2019.10306

CD44v6 may influence ovarian cancer cell invasion and migration by regulating the NF‑κB pathway

Authors:
- Yanqing Wang
- Xiao Yang
- Shu Xian
- Li Zhang
- Yanxiang Cheng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: May 3, 2019 https://doi.org/10.3892/ol.2019.10306
Pages: 298-306
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) has the worst prognosis among all malignancy types in females worldwide according to epidemiological studies in 2017. Although radiotherapy, chemotherapy and surgical treatment are the most common treatment methods, their curative effects are not satisfactory. The present study aimed to examine the role of cluster of differentiation 44 variant 6 (CD44v6) in the molecular mechanism of the proliferation and tumorigenicity of OC cells, and provide a novel target for the clinical treatment of OC. A total of 46 clinical samples were collected, including 24 malignant ovarian tumor tissue samples and 22 benign ovarian tissue samples. Expression of CD44v6 and nuclear factor‑κB (NF‑κB) in these samples was detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry. The A2780 OC cell line was used to establish a normal control group, a negative control group and a CD44v6‑small interfering (si)RNA transfection group. The expression of CD44v6 and NF‑κB mRNA was detected in each group by RT‑qPCR. The proliferation, invasion and migration abilities of the cells were then assessed by Transwell and colony formation assays. Additionally, immunofluorescence was used to detect nuclear NF‑κB expression. CD44v6 and NF‑κB mRNA expression levels were significantly increased in malignant ovarian tumor tissues, compared with normal ovarian tissues (P<0.01), and immunohistochemistry demonstrated similar results. In the CD44v6‑siRNA group, NF‑κB mRNA expression was significantly reduced, compared with the control and negative control (both P<0.01) groups. Transwell and colony formation assays demonstrated that the migration, invasion and colony formation abilities of OC cells in the CD44v6‑siRNA group were significantly reduced, compared with the control and negative control (both P<0.01) groups. Immunofluorescence results demonstrated that the expression of NF‑κB in the cytoplasm and nucleus of the CD44v6‑siRNA group was also markedly reduced, compared with the other two groups. In conclusion, CD44v6 may participate in the proliferation of OC cells through activation of the NF‑κB pathway and these observations may provide a novel therapeutic target for the clinical treatment of OC.

View Figures

View References

1	Towne SD Jr: Socioeconomic, Geospatial, and Geopolitical disparities in access to health care in the US 2011-2015. Int J Environ Res Public Health. 14:5732017. View Article : Google Scholar
2	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
3	Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer. 9:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kujawa KA and Lisowska KM: Ovarian cancer-from biology to clinic. Postepy Hig Med Dosw (Online). 69:1275–1290. 2015.(In Polish). View Article : Google Scholar : PubMed/NCBI
5	Screaton GR, Bell MV, Bell JI and Jackson DG: The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem. 268:12235–12238. 1993.PubMed/NCBI
6	Jackson DG, Buckley J and Bell JI: Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem. 267:4732–4739. 1992.PubMed/NCBI
7	Prochazka L, Tesarik R and Turanek J: Regulation of alternative splicing of CD44 in cancer. Cell Signal. 26:2234–2239. 2014. View Article : Google Scholar : PubMed/NCBI
8	Saegusa M, Machida D, Hashimura M and Okayasu I: CD44 expression in benign, premalignant, and malignant ovarian neoplasms: Relation to tumour development and progression. J Pathol. 189:326–337. 1999. View Article : Google Scholar : PubMed/NCBI
9	Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 3:8832012. View Article : Google Scholar : PubMed/NCBI
11	Zoller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI
12	Dallas MR, Liu G, Chen WC, Thomas SN, Wirtz D, Huso DL and Konstantopoulos K: Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J. 26:2648–2656. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nagano O, Okazaki S and Saya H: Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 32:5191–5198. 2013. View Article : Google Scholar : PubMed/NCBI
15	Li XP, Zhang XW, Zheng LZ and Guo WJ: Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol. 8:6724–6731. 2015.PubMed/NCBI
16	Ouhtit A, Rizeq B, Saleh HA, Rahman MM and Zayed H: Novel CD44-downstream signaling pathways mediating breast tumor invasion. Int J Biol Sci. 14:1782–1790. 2018. View Article : Google Scholar : PubMed/NCBI
17	Abbasian M, Mousavi E, Arab-Bafrani Z and Sahebkar A: The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis. J Cell Physiol. 234:8192–8202. 2019. View Article : Google Scholar : PubMed/NCBI
18	Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
19	Liotta LA, Delisi C, Saidel G and Kleinerman J: Micrometastases formation: A probabilistic model. Cancer Lett. 3:203–208. 1977. View Article : Google Scholar : PubMed/NCBI
20	Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
21	Kawano T, Nakamura Y, Yanoma S, Kubota A, Furukawa M, Miyagi Y and Tsukuda M: Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx. 31:35–41. 2004. View Article : Google Scholar : PubMed/NCBI
22	Gu H, Shang P and Zhou C: Expression of CD44v6 and E-cadherin in prostate carcinoma and metastasis of prostate carcinoma. Zhonghua Nan Ke Xue. 1032–34. (38)2004.(In Chinese). PubMed/NCBI
23	Afify AM, Tate S, Durbin-Johnson B, Rocke DM and Konia T: Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers. 26:50–57. 2011. View Article : Google Scholar : PubMed/NCBI
24	Stickeler E, Vogl FD, Denkinger T, Mobus VJ, Kreienberg R and Runnebaum IB: Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients. Int J Mol Med. 6:595–601. 2000.PubMed/NCBI
25	Sun Y, Shen Z and Ji X: Study on the relationship between CD44v6, p53 gene mutation and ovarian carcinoma metastasis. Zhonghua Fu Chan Ke Za Zhi. 35:225–228. 2000.(In Chinese). PubMed/NCBI
26	Bar JK, Grelewski P, Popiela A, Noga L and Rabczynski J: Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: Correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol. 95:23–31. 2004. View Article : Google Scholar : PubMed/NCBI
27	Hong SC, Song JY, Lee JK, Lee NW, Kim SH, Yeom BW and Lee KW: Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res. 32:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
28	Liotta LA, Delisi C, Saidel G and Kleinerman J: Micrometastases formation: A probabilistic model. Cancer Lett. 3:203–208. 1977. View Article : Google Scholar : PubMed/NCBI
29	Ricciardelli C, Lokman NA, Ween MP and Oehler MK: Women in Cancer Thematic Review: Ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 23:T155–T168. 2016. View Article : Google Scholar : PubMed/NCBI
30	Ween MP, Oehler MK and Ricciardelli C: Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci. 12:1009–1029. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhang HF, Hu P and Fang SQ: Understanding the role of CD44V6 in ovarian cancer. Oncol Lett. 14:1989–1992. 2017. View Article : Google Scholar : PubMed/NCBI
32	Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L, Franke WW, et al: A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 5:553–567. 2007. View Article : Google Scholar : PubMed/NCBI
33	Afify A, Purnell P and Nguyen L: Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 86:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
34	Sokolova O and Naumann M: NF-kB signaling in gastric cancer. Toxins (Basel). 9(pii): E1192017. View Article : Google Scholar : PubMed/NCBI
35	Olivier S, Robe P and Bours V: Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol. 72:1054–1068. 2006. View Article : Google Scholar : PubMed/NCBI
36	Xie DH, Tang XD, Xia SJ, Tan JM, Wang XH and Cai Y: Expression of NF-kappa B in human bladder cancer and its clinical significance. Ai Zheng. 21:663–667. 2002.(In Chinese). PubMed/NCBI
37	Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene. 23:2934–2949. 2004. View Article : Google Scholar : PubMed/NCBI
38	Takada Y, Kobayashi Y and Aggarwal BB: Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem. 280:17203–17212. 2005. View Article : Google Scholar : PubMed/NCBI
39	Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, Leclerc S, Moreau A and Moldovan F: Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond). 110:645–654. 2006. View Article : Google Scholar : PubMed/NCBI
40	Chen Y, Li R, Wang R and Liu Z: The significance of nuclear factor kappa Bp65 (NF kappa Bp65) expression on the vascular endothelial cells of rectum adenocarcinoma of human. Hua Xi Yi Ke Da Xue Xue Bao. 32:196–199. 2001.(In Chinese). PubMed/NCBI
41	Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M: Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res. 7:4136–4142. 2001.PubMed/NCBI
42	Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A and Lindholm PF: Requirememt of Rho A activity for increased nuclear factor kappa B activity and PC23 human prostate cancer cell invasion. Cancer Res. 63:1359–1364. 2003.PubMed/NCBI
43	Jana A, Krett NL, Guzman G, Khalid A, Ozden O, Staudacher JJ, Bauer J, Baik SH, Carroll T, Yazici C and Jung B: NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway. Oncotarget. 8:37377–37393. 2017. View Article : Google Scholar : PubMed/NCBI
44	Ning Y, Xu M, Cao X, Chen X and Luo X: Inactivation of AKT, ERK and NF-κB by genistein derivative, 7-difluoromethoxyl-5,4′-di-n-octylygenistein, reduces ovarian carcinoma oncogenicity. Oncol Rep. 38:949–958. 2017. View Article : Google Scholar : PubMed/NCBI
45	Zhang S, Leng T, Zhang Q, Zhao Q, Nie X and Yang L: Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway. Biomed Pharmacother. 102:302–308. 2018. View Article : Google Scholar : PubMed/NCBI
46	Lu Z and Chen J: Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi. 43:649–650. 2014.(In Chinese). PubMed/NCBI
47	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
48	Wang J, Xiao L, Luo CH, Zhou H, Zeng L, Zhong J, Tang Y, Zhao XH, Zhao M and Zhang Y: CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells. Mol Med Rep. 11:3505–3510. 2015. View Article : Google Scholar : PubMed/NCBI
49	Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H and Katabuchi H: CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci. 106:1421–1428. 2015. View Article : Google Scholar : PubMed/NCBI
50	Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, et al: CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 74:602–617. 2014. View Article : Google Scholar : PubMed/NCBI
51	Zhang HF, Hu P and Fang SQ: Understanding the role of CD44V6 in ovarian cancer. Oncol Lett. 14:1989–1992. 2017. View Article : Google Scholar : PubMed/NCBI
52	Shi J, Zhou Z, Di W and Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
53	Motohara T, Fujimoto K, Tayama S, Narantuya D, Sakaguchi I, Tashiro H and Katabuchi H: CD44 Variant 6 as a predictive biomarker for distant metastasis in patients with epithelial ovarian cancer. Obstet Gynecol. 127:1003–1011. 2016. View Article : Google Scholar : PubMed/NCBI
54	Pramanik KC, Makena MR, Bhowmick K and Pandey MK: Advancement of NF-κB signaling pathway: A novel target in pancreatic cancer. Int J Mol Sci. 19(pii): E38902018. View Article : Google Scholar : PubMed/NCBI
55	DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
56	Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60:5334–5339. 2000.PubMed/NCBI
57	Malinen M, Niskanen EA, Kaikkonen MU and Palvimo JJ: Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res. 45:619–630. 2017. View Article : Google Scholar : PubMed/NCBI
58	Luo JL, Maeda S, Hsu LC, Yagita H and Karin M: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297–305. 2004. View Article : Google Scholar : PubMed/NCBI
59	Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012. View Article : Google Scholar : PubMed/NCBI
60	Kawana H, Karaki H, Higashi M, Miyazaki M, Hilberg F, Kitagawa M and Harigaya K: CD44 suppresses TLR-mediated inflammation. J Immunol. 180:4235–4245. 2008. View Article : Google Scholar : PubMed/NCBI
61	Bourguignon LY, Wong G, Earle CA and Xia W: Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken). 68:671–693. 2011. View Article : Google Scholar : PubMed/NCBI